Diclofenac sodium CAS NO.15307-79-6
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID80017813
CAS NO.15307-79-6
Purity 98%
MDL NumberMFCD00082251
EINEC239-346-4
Molecular FormulaC14H10Cl2NNaO2
Molecular Weight 318.1305
Melting point: 279~289℃
| Aspect | Details |
|---|---|
| Mechanism of Action | Diclofenac sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of pro-inflammatory prostaglandins. It also down-regulates sensitized peripheral pain receptors by stimulating the L-arginine/nitric oxide (NO)/cGMP pathway. |
| Pharmacokinetics | Diclofenac sodium is rapidly absorbed when administered orally and reaches peak plasma concentrations within 1 to 2 hours. It is highly protein-bound (99%) and has a half-life of approximately 1 to 2 hours. The drug is metabolized in the liver and excreted mainly in the urine. |
| Administration | Available in various forms, including oral tablets, suspension, intramuscular injection, intravenous injection, transdermal gel, and rectal suppositories. For acute pain, intravenous bolus injections can be administered. |
| Adverse Effects | Common side effects include gastrointestinal upset, nausea, vomiting, and abdominal pain. Prolonged use may lead to gastrointestinal ulcers, bleeding, and renal impairment. |
| Storage Conditions | Diclofenac sodium should be stored at room temperature (15° to 30°C) and protected from light. |
| Special Considerations | Use with caution in patients with a history of gastrointestinal ulcers, renal impairment, or cardiovascular disease. Concurrent use with other NSAIDs or anticoagulants may increase the risk of adverse effects |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
